Literature DB >> 22544698

Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.

Saar Gill1, Adrianne E Vasey, Alysha De Souza, Jeanette Baker, Aaron T Smith, Holbrook E Kohrt, Mareike Florek, Kenneth D Gibbs, Keri Tate, David S Ritchie, Robert S Negrin.   

Abstract

Natural killer (NK) cells are potent anti-viral and antitumor "first responders" endowed with natural cytotoxicity and cytokine production capabilities. To date, attempts to translate these promising biologic functions through the adoptive transfer of NK cells for the treatment of cancer have been of limited benefit. Here we trace the fate of adoptively transferred murine NK cells and make the surprising observation that NK cells traffic to tumor sites yet fail to control tumor growth or improve survival. This dysfunction is related to a rapid down-regulation of activating receptor expression and loss of important effector functions. Loss of interferon (IFN)γ production occurs early after transfer, whereas loss of cytotoxicity progresses with homeostatic proliferation and tumor exposure. The dysfunctional phenotype is accompanied by down-regulation of the transcription factors Eomesodermin and T-bet, and can be partially reversed by the forced overexpression of Eomesodermin. These results provide the first demonstration of NK-cell exhaustion and suggest that the NK-cell first-response capability is intrinsically limited. Further, novel approaches may be required to circumvent the described dysfunctional phenotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544698      PMCID: PMC3382935          DOI: 10.1182/blood-2012-03-415364

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells.

Authors:  Michael J Townsend; Amy S Weinmann; Jennifer L Matsuda; Rachelle Salomon; Peggy J Farnham; Christine A Biron; Laurent Gapin; Laurie H Glimcher
Journal:  Immunity       Date:  2004-04       Impact factor: 31.745

2.  NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation.

Authors:  Nicholas D Huntington; Hy Tabarias; Kirsten Fairfax; Jason Brady; Yoshihiro Hayakawa; Mariapia A Degli-Esposti; Mark J Smyth; David M Tarlinton; Stephen L Nutt
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

3.  Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells.

Authors:  Scott H Robbins; Khuong B Nguyen; Nobuaki Takahashi; Toshifumi Mikayama; Christine A Biron; Laurent Brossay
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 4.  NK cell development, homeostasis and function: parallels with CD8⁺ T cells.

Authors:  Joseph C Sun; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2011-08-26       Impact factor: 53.106

5.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands.

Authors:  Marco Wendel; Ioanna E Galani; Elisabeth Suri-Payer; Adelheid Cerwenka
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

6.  Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.

Authors:  Janelle A Olson; Robert Zeiser; Andreas Beilhack; Joshua J Goldman; Robert S Negrin
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

7.  Control of effector CD8+ T cell function by the transcription factor Eomesodermin.

Authors:  Erika L Pearce; Alan C Mullen; Gislâine A Martins; Connie M Krawczyk; Anne S Hutchins; Valerie P Zediak; Monica Banica; Catherine B DiCioccio; Darrick A Gross; Chai-An Mao; Hao Shen; Nezih Cereb; Soo Y Yang; Tullia Lindsten; Janet Rossant; Christopher A Hunter; Steven L Reiner
Journal:  Science       Date:  2003-11-07       Impact factor: 47.728

8.  Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.

Authors:  Hollie J Pegram; Jacob T Jackson; Mark J Smyth; Michael H Kershaw; Phillip K Darcy
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection.

Authors:  Charlly Kao; Kenneth J Oestreich; Michael A Paley; Alison Crawford; Jill M Angelosanto; Mohammed-Alkhatim A Ali; Andrew M Intlekofer; Jeremy M Boss; Steven L Reiner; Amy S Weinmann; E John Wherry
Journal:  Nat Immunol       Date:  2011-05-29       Impact factor: 25.606

View more
  81 in total

1.  The breast tumor microenvironment alters the phenotype and function of natural killer cells.

Authors:  Tamara Krneta; Amy Gillgrass; Marianne Chew; Ali A Ashkar
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

2.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Authors:  Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts
Journal:  Cancer Immunol Res       Date:  2019-07-30       Impact factor: 11.151

3.  The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells.

Authors:  Tiffany Hughes; Edward L Briercheck; Aharon G Freud; Rossana Trotta; Susan McClory; Steven D Scoville; Karen Keller; Youcai Deng; Jordan Cole; Nicholas Harrison; Charlene Mao; Jianying Zhang; Don M Benson; Jianhua Yu; Michael A Caligiuri
Journal:  Cell Rep       Date:  2014-06-19       Impact factor: 9.423

Review 4.  Umbilical cord blood graft engineering: challenges and opportunities.

Authors:  P A Thompson; K Rezvani; C M Hosing; B Oran; A L Olson; U R Popat; A M Alousi; N D Shah; S Parmar; C Bollard; P Hanley; P Kebriaei; L Cooper; J Kellner; I K McNiece; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

5.  Reversal of natural killer cell exhaustion by TIM-3 blockade.

Authors:  Anne Gallois; Ines Silva; Iman Osman; Nina Bhardwaj
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

6.  NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.

Authors:  Cordelia Dunai; William J Murphy
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

7.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

8.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

9.  A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Authors:  Gabriela Maria Wiedemann; Severin Johannes Jacobi; Michael Chaloupka; Angelina Krächan; Svetlana Hamm; Stefan Strobl; Roland Baumgartner; Simon Rothenfusser; Peter Duewell; Stefan Endres; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2016-05-31       Impact factor: 8.110

10.  Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation.

Authors:  Molly P Keppel; Liping Yang; Megan A Cooper
Journal:  J Immunol       Date:  2013-03-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.